Posted by Michael Wonder on 29 Jul 2026
Nidlegy marketing authorisation application resubmitted to EMA
27 July 2026 - Philogen is pleased to announce the submission of an updated marketing authorisation application to the EMA for the approval of Nidlegy, an investigational product for the neo-adjuvant treatment of adult patients with locally advanced, fully resectable melanoma.
The updated submission is based on clinical data from the randomised Phase 3 PIVOTAL study (PHL19IL2TNF-02/15).
